MUMBAI, India, Aug. 1 -- Intellectual Property India has published a patent application (202527067979 A) filed by Jiangsu Hengrui Pharmaceuticals Co. Ltd.; and Shanghai Shengdi Pharmaceutical Co. Ltd., Jiangsu, China, on July 16, for 'anti-her2 antibody-drug conjugate for treating breast cancer.'
Inventor(s) include Wang, Quanren.
The application for the patent was published on Aug. 1, under issue no. 31/2025.
According to the abstract released by the Intellectual Property India: "Use of an anti-HER2 antibody-drug conjugate in the preparation of a drug for treating HER2 low-expression breast cancer. The structure of the antibody-drug conjugate is represented by formula (I)."
The patent application was internationally filed on Jan. 19, 2024, under International application No.PCT/CN2024/073246.
Disclaimer: Curated by HT Syndication.
